Phaseline

Targets › FCGR3A

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Sep 2027.

Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). (UniProt, P08637)

Open in Phaseline: the race on FCGR3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwestbemarituzumab
Fibroblast growth factor receptor 2 inhibitor; Low affinity immunoglobulin gamma Fc region receptor III-A binding agent
FGFR2, FCGR3APhase 2Metastatic Gastro-esophageal AdenocarcinomaSep 2027
Chunji GaoDonor-derived CD123-CD16 bispecific antibody-modified NK cells
CD123-CD16 bispecific antibody-modified NK cells for AML targeting
CD123, FCGR3APhase 1AML (Acute Myelogenous Leukemia)–

Conditions

Metastatic Gastro-esophageal Adenocarcinoma (1) AML (Acute Myelogenous Leukemia) (1)

Modalities

antibody (1), other (1)

Companies

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) Chunji Gao (1)

Related targets

FGFR2 (1) CD123 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.